Initiating beta-blockers during the in-hospital phase has been shown to improve the prognosis for patients with HFrEF, as evidenced by the STRONG-HF study (The Safety, Tolerability, and Efficacy of Rapid Optimization, Helped by NT-proBNP Testing, of Heart Failure Therapies) [6]. This evidence concerns the gene NPPB and heart failure.